Another reason the best "publicity" for us is in scientific journals is the risk of being perceived as a pump and dump. Waving a flag too hard before the documentation (successful trials) and commercial viability can be established can be dangerous.

I have never seen the stock price over 20 US, or even anywhere near, but have heard that it went there prior to release of one of the earlier trial results. Don't see that on the charts though, so not sure. But those tumbles create bigger obstacles. 

Better to delay a solid rise than to increase the kinds of risks and obstacles that come with not being taken seriously and a jump that the market decides is unwarranted.

Hope we see something soon in clinicaltrials.gov. He did mention April latest.